EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The GPCR antagonist PPTN synergizes with caspofungin providing increased fungicidal activity against Aspergillus fumigatus

Thaila Fernanda Dos Reis iD, Endrews Delbaje, Camila Figueiredo Pinzan, Rafael Bastos, Suzanne Ackloo, Sara Fallah, Bradley Laflamme iD, Nicole Robbins, Leah E Cowen iD, Gustavo H Goldman iD

Microbiology Spectrum · 2025

DOI: 10.1128/spectrum.03318-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, 2025. Verfasst von Thaila Fernanda Dos Reis und 9 weiteren Autor:innen. Beteiligte Einrichtung: Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, São Paulo, Brazil. Hauptthemen laut MEDLINE: Aspergillus fumigatus, Antifungal Agents, Caspofungin, Naphthalenes. Die Arbeit nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fungal pathogens pose a serious threat to human health, with Candida and Aspergillus spp. representing some of the most significant opportunistic invaders. Aspergillus fumigatus causes aspergillosis, one of the most prevalent fungal diseases of humans. There is a limited number of drugs available to combat these infections, and antifungal drug resistance is on the rise. In this manuscript, we show 4-[4-(4-Piperidinyl) phenyl]-7-[4-(-(trifluoromethyl) phenyl]-2-naphthalenecarboxylic acid (PPTN), a highly specific antagonist of the human P2Y14 receptor, is a promising antifungal adjuvant against diverse fungal pathogens. PPTN interacts with caspofungin (CAS), ibrexafungerp, voriconazole (VOR), and amphotericin against A. fumigatus CAS- and VOR-resistant clinical isolates, and also CAS against Candida spp and Cryptococcus neoformans . The combination of PPTN and CAS increases cell death in A. fumigatus . In the model yeast Saccharomyces cerevisiae, heterozygous deletion of genes involved in chromatin remodeling results in PPTN hypersensitivity, and in A. fumigatus , PPTN can have increased fungicidal activity when combined with the histone deacetylase inhibitor trichostatin A and the DNA methyltransferase inhibitor 5-azacytidine. Finally, PPTN has reduced toxicity to human immortalized cell lineages and partially clears A. fumigatus conidia infection in A549 pulmonary epithelial cells. Our results indicate that PPTN is a novel adjuvant antifungal drug against fungal diseases caused by A. fumigatus and Candida spp. IMPORTANCE Invasive fungal infections have a high mortality rate, causing more deaths annually than tuberculosis or malaria. Aspergillus fumigatus is the main etiological agent of aspergillosis, one of the most prevalent and deadly fungal diseases. There are few therapeutic options for treating this disease, and treatment commonly fails due to host complications or the emergence of antifungal resistance. Drug repurposing, where existing drugs are deployed for other clinical indications, has increasingly been used in the process of drug discovery. Here, we show that 4-[4-(4-Piperidinyl) phenyl]-7-[4-(-(trifluoromethyl) phenyl]-2-naphthalenecarboxylic acid (PPTN), a highly specific antagonist of the human P2Y14 receptor, when combined with caspofungin (CAS), ibrexafungerp, voriconazole (VOR), and amphotericin can increase the fungicidal activity against not only A. fumigatus CAS- and VOR-resistant clinical isolates but also CAS against Candida spp.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aspergillus fumigatusAntifungal AgentsCaspofunginNaphthalenesReceptors, G-Protein-CoupledHumansMicrobial Sensitivity TestsDrug SynergismAspergillosisSaccharomyces cerevisiaeDrug Resistance, FungalCandida

Stichwörter der Autor:innen

Aspergillus fumigatusCandida sppCryptococcus neoformansPPTNcaspofungin

Substanzen

Antifungal AgentsCaspofunginNaphthalenesReceptors, G-Protein-Coupled

Autor:innen und Institutionen

  • Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, São Paulo, Brazil.
  • National Institute of Science and Technology in Human Pathogenic Fungi, São Paulo, Brazil.
  • Centro de Biociências, Universidade Federal do Rio Grande do Norte, Natal, Brazil.
  • Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada.
  • Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.

ORCID-Profile: Thaila Fernanda Dos Reis, Bradley Laflamme, Leah E Cowen, Gustavo H Goldman

Förderung

  • NIAID NIH HHS
  • Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
  • HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
  • Canadian Government | Canadian Institutes of Health Research (CIHR)

Zitieren

APA

Dos Reis, T. F., Delbaje, E., Pinzan, C. F., Bastos, R., Ackloo, S., Fallah, S., Laflamme, B., Robbins, N., Cowen, L. E., & Goldman, G. H. (2025). The GPCR antagonist PPTN synergizes with caspofungin providing increased fungicidal activity against Aspergillus fumigatus. Microbiology Spectrum. https://doi.org/10.1128/spectrum.03318-24

Vancouver

Dos Reis TF, Delbaje E, Pinzan CF, Bastos R, Ackloo S, Fallah S, et al. The GPCR antagonist PPTN synergizes with caspofungin providing increased fungicidal activity against Aspergillus fumigatus. Microbiology Spectrum. 2025. doi:10.1128/spectrum.03318-24

BibTeX
@article{DosReis2025,
  author = {Dos Reis, Thaila Fernanda and Delbaje, Endrews and Pinzan, Camila Figueiredo and Bastos, Rafael and Ackloo, Suzanne and Fallah, Sara and Laflamme, Bradley and Robbins, Nicole and Cowen, Leah E and Goldman, Gustavo H},
  title = {The GPCR antagonist PPTN synergizes with caspofungin providing increased fungicidal activity against Aspergillus fumigatus},
  journal = {Microbiology Spectrum},
  year = {2025},
  doi = {10.1128/spectrum.03318-24}
}
Kostenlos starten →